227 related articles for article (PubMed ID: 33234363)
21. Combination of tanshinone IIA and doxorubicin possesses synergism and attenuation effects on doxorubicin in the treatment of breast cancer.
Li K; Liu W; Zhao Q; Wu C; Fan C; Lai H; Li S
Phytother Res; 2019 Jun; 33(6):1658-1669. PubMed ID: 30945389
[TBL] [Abstract][Full Text] [Related]
22. Enhanced antitumor activity and attenuated cardiotoxicity of Epirubicin combined with Paeonol against breast cancer.
Wu J; Xue X; Zhang B; Cao H; Kong F; Jiang W; Li J; Sun D; Guo R
Tumour Biol; 2016 Sep; 37(9):12301-12313. PubMed ID: 27272157
[TBL] [Abstract][Full Text] [Related]
23. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
24. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
[TBL] [Abstract][Full Text] [Related]
25. Glycyrrhetinic acid remodels the tumor microenvironment and synergizes with doxorubicin for breast cancer treatment in a murine model.
Tang M; Yang M; He K; Li R; Chen X; Wang Y; Zhang X; Qiu T
Nanotechnology; 2021 Apr; 32(18):185702. PubMed ID: 33503591
[TBL] [Abstract][Full Text] [Related]
26. Disruption of mitochondrial homeostasis with artemisinin unravels anti-angiogenesis effects via auto-paracrine mechanisms.
Tsui KH; Wu MY; Lin LT; Wen ZH; Li YH; Chu PY; Li CJ
Theranostics; 2019; 9(22):6631-6645. PubMed ID: 31588240
[No Abstract] [Full Text] [Related]
27. Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro.
Shamshiripour P; Rahnama M; Nikoobakht M; Rad VF; Moradi AR; Ahmadvand D
J Control Release; 2024 May; 369():128-145. PubMed ID: 38522817
[TBL] [Abstract][Full Text] [Related]
28. Hsp90 Inhibitor; NVP-AUY922 in Combination with Doxorubicin Induces Apoptosis and Downregulates VEGF in MCF-7 Breast Cancer Cell Line.
Mohammadian M; Feizollahzadeh S; Mahmoudi R; Toofani Milani A; Rezapour-Firouzi S; Karimi Douna B
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1773-1778. PubMed ID: 32592377
[TBL] [Abstract][Full Text] [Related]
29. The synergistic effect between vanillin and doxorubicin in ehrlich ascites carcinoma solid tumor and MCF-7 human breast cancer cell line.
Elsherbiny NM; Younis NN; Shaheen MA; Elseweidy MM
Pathol Res Pract; 2016 Sep; 212(9):767-77. PubMed ID: 27493101
[TBL] [Abstract][Full Text] [Related]
30. Magnoflorine improves sensitivity to doxorubicin (DOX) of breast cancer cells via inducing apoptosis and autophagy through AKT/mTOR and p38 signaling pathways.
Wei T; Xiaojun X; Peilong C
Biomed Pharmacother; 2020 Jan; 121():109139. PubMed ID: 31707337
[TBL] [Abstract][Full Text] [Related]
31. QbD-based development of α-linolenic acid potentiated nanoemulsion for targeted delivery of doxorubicin in DMBA-induced mammary gland carcinoma: in vitro and in vivo evaluation.
Tripathi CB; Parashar P; Arya M; Singh M; Kanoujia J; Kaithwas G; Saraf SA
Drug Deliv Transl Res; 2018 Oct; 8(5):1313-1334. PubMed ID: 29748834
[TBL] [Abstract][Full Text] [Related]
32. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis.
Chen J; Wang W; Wang H; Liu X; Guo X
Drug Discov Ther; 2014 Feb; 8(1):33-41. PubMed ID: 24647156
[TBL] [Abstract][Full Text] [Related]
33. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
[TBL] [Abstract][Full Text] [Related]
34. Enhancing therapeutic efficacy in breast cancer: a study on the combined cytotoxic effects of doxorubicin and MPC-3100.
Gökşen Tosun N
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3249-3259. PubMed ID: 37917369
[TBL] [Abstract][Full Text] [Related]
35. Anti-angiogenic effects of Qingdu granule on breast cancer through inhibiting NFAT signaling pathway.
Zhao X; Liu J; Feng L; Ge S; Yang S; Chen C; Li X; Peng L; Mu Y; Wang Y; Gu D; Guo Y; Lin G; Deng B; Cheng Z; Cai D
J Ethnopharmacol; 2018 Aug; 222():261-269. PubMed ID: 29337215
[TBL] [Abstract][Full Text] [Related]
36. Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer.
Feng C; Zhang H; Chen J; Wang S; Xin Y; Qu Y; Zhang Q; Ji W; Yamashita F; Rui M; Xu X
Int J Pharm; 2019 Apr; 560():191-204. PubMed ID: 30769131
[TBL] [Abstract][Full Text] [Related]
37. The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer.
Chiu CF; Lin YQ; Park JM; Chen YC; Hung SW; Chiu CC; Chang CF
Biomed Pharmacother; 2020 Aug; 128():110309. PubMed ID: 32505820
[TBL] [Abstract][Full Text] [Related]
38. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
39. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
[TBL] [Abstract][Full Text] [Related]
40. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes.
Eid SY; Althubiti MA; Abdallah ME; Wink M; El-Readi MZ
Phytomedicine; 2020 Oct; 77():153280. PubMed ID: 32712543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]